Effects of CoCl₂ on multi-lineage differentiation of C3H/10T1/2 mesenchymal stem cells

Hong Il Yoo¹,*, Yeon Hee Moon²,*, and Min Seok Kim¹*

¹Department of Oral Anatomy, School of Dentistry, Chonnam National University, Gwangju 61186, ²Department of Dental Hygiene, Chodang University, Muan 58530, Korea

INTRODUCTION

Mesenchymal stem cells (MSCs) are multipotent cells that can expanded ex vivo and induced in vitro or in vivo to terminally differentiate into multiple lineages that include osteocytes, chondrocytes, and adipocytes [1,2]. Stem cells located in bone marrow, around blood vessels, fat, skin, tooth, and other niches are crucial in tissue repair [1,3]. MSCs from different tissues are distinct biologically [4]. For example, MSCs derived from bone marrow show a higher potential for osteogenic differentiation, while MSCs of synovial origin show a greater tendency toward chondrogenic differentiation [5,6]. The recent use of autologous or allogenic stem cells has been suggested as an alternative therapeutic approach for tissue engineering and cell-based therapies [7].

Bone marrow is a hypoxic environment in which the oxygen tension ranges from 1 to 7%. Thus, MSCs should be cultured under hypoxic and normoxic conditions and the findings compared to determine the effects of bone marrow niche of MSCs [8]. However, it is not easy to simulate the in vivo hypoxic environment in culture. This information is important given the burgeoning interest in regenerative medicine for tissue ischemia events like cardiac arrest and transplantation failure [9]. Several studies have addressed the effects of hypoxia on MSCs. The findings have been equivocal [10-12]. Some reports demonstrated that human bone marrow-derived MSCs cultured under hypoxia showed a diminished capacity to differentiate into adipocytes and osteocytes, supporting the notion that low oxygen tension promotes an undifferentiated state [13,14]. But, other reports demonstrated that MSCs expanded under reduced oxygen tension and were primed for chondrogenic differentiation.
In addition, hypoxic conditions promote chondrogenic differentiation and enhance cartilage protein synthesis through the upregulation of Sox9, type II collagen, and aggrecan. Moreover, a recent report demonstrated that hypoxic culture conditions promote chondrogenic, osteogenic, and adipogenic differentiation, and that hypoxic cells show an increased bone repair ability in vivo. The oxygen concentration in culture is a crucial factor that can significantly influence the proliferation and differentiation potentials of MSCs. The role of hypoxia in the differentiation of MSCs remains unclear.

CoCl₂ reportedly induces molecular responses similar to low-oxygen conditions in mammalian systems. The lack of oxygen can create a potentially lethal environment and limits cellular respiration and growth. Alternatively, lack of oxygen can enhance the production of specific extracellular matrix components and increase angiogenesis through the oxygen. Hypoxia can enhance the production of the specific extracellular matrix components and increase angiogenesis through the oxygen can enhance the production of the specific extracellular matrix components and increase angiogenesis through the oxygen can enhance the production of the specific extracellular matrix components and increase angiogenesis through the oxygen.

The aim of this study was to elucidate the potential role of CoCl₂ by examining the effects of CoCl₂ exposure on lineage differentiation of C3H/10T1/2 cells including osteogenic, chondrogenic and adipogenic capacity, and to understand the possible molecular mechanisms of CoCl₂ during in vitro culture.

**METHODS**

**Cell culture**

Murine C3H/10T1/2 MSCs were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco BRL, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS; Gibco BRL) and 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco BRL). The cells were incubated at 37°C and 5% CO₂. Protein quantification was performed with BCA protein assay (Bio-Rad, Hercules, CA, USA), with each expression calculated relative to mouse 

**Cell viability assay**

The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-based EZ-Cytox assay (Daeil Lab Service, Seoul, South Korea) was used to measure cell viability. C3H/10T1/2 cells were seeded in 96-well culture plates at a density of 0.5×10⁴ cells/100 ml in each well and pre-incubated in growth medium for 24 h at 37°C and 5% CO₂. The culture medium was changed to fresh DMEM containing 2% FBS and 1% antibiotics, and treated with 0.1 mM CoCl₂. After 24 h, each well was washed twice with phosphate buffered saline (PBS), and 0.5 ml of medium and 50 µl of a 5 mg/ml PBS solution of MTT (Invitrogen, Carlsbad, CA, USA) was added. After 3-h incubation, the MTT-containing medium was removed and 250 µl dimethylsulfoxide (DMSO; Invitrogen) was added. The absorbance of the reaction solution was measured at 570 nm using a Microplate ELISA Autoreader (BIO-Tek Instruments, Winooski, VT, USA). The reported value represents the average of three independent experiments.

**Reverse transcriptase-polymerase chain reaction (RT-PCR) and real-time quantitative RT-PCR (qRT-PCR)**

Total cellular RNA was prepared using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. Complementary DNA (cDNA) was synthesized with 5 µg RNA using an AccPower RT PreMix kit (Bioneer, Daejeon, Korea) at 45°C for 60 min, and then at 95°C for 5 min. After cDNA synthesis, primers were added and PCR was performed in a SuperCycler™ apparatus (Kyratec, Queensland, Australia) using 30 cycles of 94°C for 5 min, 94°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec, followed by 72°C for 5 min. Preliminary experiments were performed to determine the optimum number of PCR cycles. PCR products were analyzed by 1.5% agarose gel electrophoresis and visualized with SYBR® Green nucleic acid gel stain (Invitrogen). Primer sequences used are shown in Table 1. qRT-PCR was performed using cDNA and specific primers as the template in a 20 µl reaction mixture containing 2×Quantimix SYBR (PKT, Seoul, Korea). Analysis was carried out using the software supplied with the one-step, real-time PCR System machine (Applied Biosystems, Franklin Lakes, NJ, USA), with each expression calculated relative to mouse β-actin (delta CT) and controls (delta delta CT) using the fluorescence threshold for the amplification reaction and the comparative CT method.

**Western blot analysis**

C3H/10T1/2 cells were plated at a density of 2×10⁴ cells in 60-mm culture dishes with DMEM containing 10% FBS and 1% antibiotics. After 24 h, the medium was changed to DMEM supplemented with 2% FBS and 1% antibiotics, and exposed to 0.1 mM CoCl₂. At the indicated times, medium was removed and adherent cells were washed twice with PBS, homogenized in lysis buffer (Cell Signaling Technology, Beverly, MA, USA), and centrifuged at 13,000 rpm for 10 min at 4°C. Protein quantification was performed with BCA protein assay (Bio-Rad, Hercules, CA, USA). Total protein was resolved by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
and the resolved proteins were electrophoretically transferred to a polyvinylidene difluoride (PVDF) membrane. After blocking in Tris-buffered saline containing 5% skim milk and 0.1% Tween-20 (TBS-T), the membrane was incubated with a specific primary antibody to HIF-1α (diluted 1:1000; R&D Systems, Minneapolis, MN, USA) or actin (diluted 1:5000; Sigma-Aldrich) diluted 1:1,000 in 5% bovine serum albumin or skim milk in TBS-T by gentle agitation overnight at 4°C. After washing with TBS-T, each blot was incubated with anti-mouse secondary antibody (1:5,000 dilution; Cell Signaling Technology) at room temperature for 1 h. The membrane was then washed with TBS-T (3×10 min). The antigen-antibody complexes were visualized with West-ZOL ™ (plus) (iNtRON Biotechnology, Sungnam, Korea) detection reagent using a LAS-4000 mini imager (Fuji Film, Tokyo, Japan).

### Osteogenic induction

C3H/10T1/2 cells were plated at a density of 2×10⁵ cells/plate in 35-mm culture dishes with DMEM containing 10% FBS and 1% antibiotics. After 24 h, the cells were cultured with 0.1 mM CoCl₂ for 24 or 48 h, and the medium was replaced with an osteogenic medium comprised of DMEM with 10% FBS, 5 mM β-glycerophosphate (β-GP), 50 μg/ml L-ascorbic acid 2-phosphate, 200 μg/ml bone morphogenetic protein 2 (BMP2; Cowellmedi, Seoul, Korea) in the presence or absence of 0.1 mM CoCl₂. The osteogenic medium was replaced every 3 days. After 18 days of osteogenic differentiation, cells were washed with PBS, fixed with 70% ethanol, and treated with 40 nM Alizarin red S solution (Sigma-Aldrich) for 10 min to stain the calcium deposits. The stained cultures were photographed, and the Alizarin red S staining was quantified spectrophotometrically at 570 nm using an ELISA reader (BIO Tek Instruments).

### Chondrogenic induction

C3H/10T1/2 cells were incubated at 2×10⁵ cells/plate and allowed to adhere overnight. The cells were cultured in DMEM containing 2% FBS in the presence of 0.1 mM CoCl₂ for 24 or 48 h. Cells were harvested by centrifugation in a 15 ml polypropylene tube, and the pellets were cultured in a chondrogenic medium (Gibco BRL) for 3, 7, 10, and 14 days. The chondrogenic medium was replaced every 3 days. Alcian blue staining was used to detect chondrocyte nodule formation after 14 days of culture. Cells in micromass culture were rinsed with PBS and fixed in 10% formaldehyde in PBS for 20 min. Cultures were washed with water three times and stained in 1% Alcian blue (Sigma-Aldrich) with 3% glacial acetic acid for 24 h. Cultures were de-stained in 70% ethanol two times and stored in water for image capture.

### Table 1. Primer sequences for RT-PCR

| Gene   | Sequence (5’ to 3’)                                                                 | Amplicon (bp) | Genbank No.  |
|--------|-------------------------------------------------------------------------------------|---------------|--------------|
| HIF-1α | Sense AATGAGAGAAATGCTTACAC                                                         | 292           | NM_010431.2  |
|        | Antisense CTGAGTTTGGTACTCTTG                                                          |               |              |
| VEGF   | Sense GTGTGCCGCTGTAGGCGCTG                                                          | 292           | NM_001287057.1 |
|        | Antisense GCCCTTGCAAGCGAGTCTGT                                                        |               |              |
| OCN    | Sense TGAACAGACTCCGGCGCTCA                                                        | 172           | NM_007541.2  |
|        | Antisense AGGGCGACACAGGTCCTA                                                       |               |              |
| OPN    | Sense GCGGAGGTGATAGCTGGT                                                            | 177           | NM_001204201.1 |
|        | Antisense TGATAGAGGGGAGTCTG                                                          |               |              |
| COL1   | Sense AACCACAGGAGAAAAGAAGCA                                                       | 248           | NM_007742.3  |
|        | Antisense CTGAGCTCGACTCTTG                                                         |               |              |
| ALP    | Sense TATGGTAAACGGCGCTGCTAC                                                       | 187           | NM_007431.2  |
|        | Antisense TGCTCATGGAGCCGCTGAGAAGCA                                                 |               |              |
| Runx2  | Sense CGAGGAGCTGTTCAAGCTAGT                                                       | 157           | NM_001146038.2 |
|        | Antisense ACATGCGGAGCATGCCGCT                                                    |               |              |
| PPARγ  | Sense ATTCCTCAGTGAGACGCGCC                                                        | 165           | NM_011146.3  |
|        | Antisense GACCATCTGCTAGGTCG                                                       |               |              |
| C/EBPα | Sense TTGGGCTGCTGCTGAATCTCA                                                        | 164           | NM_007678.3  |
|        | Antisense TCAAGGAGAAGCACACGG                                                        |               |              |
| aP2    | Sense AAATACCCGCGACAGCAGG                                                          | 143           | NM_024406.2  |
|        | Antisense CATAAACACATTCCACACACG                                                   |               |              |
| Aggrecan | Sense TACGAGATCAGCTTCCTGGT                                                        | 134           | NM_007424.2  |
|        | Antisense TTGTAGCTGTTGGGCTG                                                        |               |              |
| Col2A1 | Sense CGAGGACACAGACTCTTTGA                                                        | 171           | NM_00113515.2 |
|        | Antisense CAGTATGCTTCCTTCAC                                                        |               |              |
| Sox9   | Sense GTGAAGAAGCCAACAGCAG                                                        | 153           | NM_011448.4  |
|        | Antisense CTGAGATTCGCGACAGTCG                                                      |               |              |
| β-actin | Sense GATCTGGCCACACACCTTCT                                                        | 138           | NM_007393.3  |
|        | Antisense GGGGTGTTGGAAGGGTCAA                                                      |               |              |
Adipogenic induction

Cells were seeded on 24-well plates at 2×10^4 cells/well and exposed to 0.1 mM CoCl_2 for 24 or 48 h. To induce adipogenic differentiation, C3H/10T1/2 cells were incubated in 0.05 mM indomethacin, 0.1 μM dexamethasone, and 5 μg insulin (Sigma-Aldrich) for 5 days. Cells were stained with 60% saturated oil red O solution (Sigma-Aldrich) for 20 min, washed with PBS, and fixed in 4% formalin in PBS for 30 min. The formalin was removed and the fixed cells were washed twice with PBS. To quantify the degree of lipid accumulation, cells were incubated with isopropanol to extract lipid and the oil red O staining intensity was quantified at 570 nm using an ELISA reader (BIO Tek Instruments).

Statistical analysis

Statistical analysis was performed using a two-tailed t-test with GraphPad Prism 4.0 for Windows (GraphPad Software, San Diego, CA, USA). A p-value<0.05 indicated statistical significance. All values are expressed as the mean±standard deviation obtained from three independent experiments.

RESULTS

Time- and dose-dependent viability kinetics of CoCl_2 treated C3H/10T1/2 cells

To examine the effect of CoCl_2 on viability of C3H/10T1/2 cells, the MTT-based assay was performed after incubation with 0.1~5 mM CoCl_2 for 2 days. CoCl_2 did not affect the viability of MSC cells concentrations <0.25 mM (Fig. 1A), while viability decreased in a dose-dependent manner at 0.5, 1, and 5 mM CoCl_2. The time-dependent effect of CoCl_2 on cell viability was ascertained 24, 48, 72, and 96 h after adding CoCl_2. CoCl_2 concentrations of 0.1 and 0.25 mM were not cytotoxic (Fig. 1B). Therefore, 0.1 mM CoCl_2 was used for experiments.
CoCl$_2$ increases expressions of HIF-1$\alpha$ and VEGF

The transition metal cobalt mimics hypoxia by stabilizing HIF-1$\alpha$, a marker of hypoxia [24]. To confirm CoCl$_2$-mediated hypoxia, mRNA expression of HIF-1$\alpha$ and VEGF were evaluated by RT-PCR after CoCl$_2$ treatment for 6, 12, 24, and 48 h. Expression of HIF-1$\alpha$ mRNA was significantly increased at 24 h compared to the control (Fig. 2A). qRT-PCR revealed that the gradual increase of HIF-1$\alpha$ mRNA in CoCl$_2$ treated samples (Fig. 2B). To investigate the protein level change of HIF-1$\alpha$ by CoCl$_2$...
treatment, Western blot was carried out. Protein levels of HIF-1α were significantly enhanced in a time-dependent manner (Fig. 2C). It could be concluded that CoCl₂ successfully mimicked hypoxic condition in vitro in cultured C3H/10T1/2 cells.

**CoCl₂ enhances osteogenic differentiation of C3H/10T1/2 cells**

To determine whether CoCl₂ treatment modulates osteoblastic differentiation, C3H/10T1/2 cells were pre-incubated with 0.1 mM CoCl₂ for 0, 24, or 48 h, and mineralized nodule formation was assessed by Alizarin Red-S staining. CoCl₂ significantly enhanced matrix mineralization, compared with control (Figs. 3A and 3B). RT-PCR revealed the significant up-regulation of the expression of osteogenic markers type I collagen (Col I), alkaline phosphatase (ALP), and Runx-related transcription factor 2 (Runx2) in CoCl₂ treated group compared with control. Expressions of osteocalcin (OCN) and osteopontin (OPN) mRNA were slightly affected by treatment of CoCl₂ (Fig. 3C). To assess the effect of CoCl₂ during osteoblast differentiation, qRT-PCR analysis was carried out to assess the gene expression of the osteogenic markers OCN, OPN, ALP, Runx2, and Col I. In pre-incubation with CoCl₂ for 24 h, OCN mRNA expression was increased about 2- and 1.5-fold in CoCl₂ treatment cells after 7 and 10 days, respectively. Also, the mRNA expression of OPN increased about 3.9-fold and ALP increased about 9-fold in the treatment group after 10 days at 24 h of CoCl₂ incubation sample. However, the expression level of Runx2 and Col I mRNA had no statistically significant variation (Fig. 3D). These results indicate that treatment of CoCl₂ partially enhances osteogenic differentiation and matrix mineralization on C3H/10T1/2 cells.

![Fig. 4. Effects of treatment of CoCl₂ on the chondrogenic differentiation.](image-url)

(A) C3H/10T1/2 cells were pre-incubated with 0.1 mM CoCl₂ for 0 h, 24 h, or 48 h. After incubation, the cells shifted to a chondrogenic medium and cultured for 14 days. The cells were then stained with Alcian blue. (B) C3H/10T1/2 cells were pre-incubated with 0.1 mM CoCl₂ for 0 h, 24 h, or 48 h. After incubation, the cells were shifted to a chondrogenic medium and cultured for 3 days. Total cellular RNA was extracted and gene expression of the chondrogenic markers aggrecan, sox9, and Col 2A1 was assessed by semi-quantitative RT-PCR. Expression of actin was examined in the same sample as a control for the amount of present reverse-transcribed cDNA. (C) Effects of treatment of CoCl₂ during chondrocyte differentiation. C3H/10T1/2 cells were pre-incubated with 0.1 mM CoCl₂ for 0 h, 24 h, or 48 h. After incubation, the cells were replaced with chondrogenic medium and cultured for 10 days. At indicated times, total cellular RNA was extracted and gene expression of the chondrogenic makers aggrecan, sox9, and Col 2A1 was assessed by qRT-PCR. Values shown are normalized to β-actin levels.
CoCl₂ enhances chondrogenic differentiation of C3H/10T1/2 cells

To examine effects of hypoxia on chondrogenesis in vitro, C3H/10T1/2 cells were pre-incubated with 0.1 mM CoCl₂ for 0, 24, or 48 h. After incubation, the cells were shifted to chondrogenic medium and cultured for 14 days. CoCl₂ treatment was associated with increased Alcian blue staining compared to control (Fig. 4A). Gene expression of chondrocyte-specific markers was evaluated by RT-PCR. The SRY-box containing gene 9 (sox9), a key transcription factor for chondrocyte differentiation, was slightly increased at 24 h of CoCl₂ incubation. The mRNA level of Aggrecan and type II collagen (Col 2A1), the downstream targets of Sox9, were significantly up-regulated in CoCl₂ treated cells at 48 h of CoCl₂ incubation (Fig. 4B). To assess the quantitative change of mRNA expression after CoCl₂ treatment during chondrocyte differentiation, qRT-PCR analysis for the gene expression of the chondrogenic markers aggrecan, Sox9, and Col 2A1 was performed. Aggrecan and Sox9 mRNA level was significantly increased about 27-fold and 4-fold at 3 days after 48 h of CoCl₂ treatment, respectively. Col2A1 mRNA level was also increased at 3 days after 24 or 48 h of CoCl₂ treatment.
CoCl₂ suppresses adipogenic differentiation of C3H/10T1/2 cells

To examine the effect of hypoxia on adipogenesis in vitro, C3H/10T1/2 cells were pre-treated with 0.1 mM CoCl₂ for 0, 24, or 48 h. After 5 days incubation, lipid droplet was assessed by oil red O staining. Both of CoCl₂ treated group significantly inhibited proliferation of cell and lipid formation compare to the control group (Fig. 5A and 5B). To determine whether hypoxic environment regulate the adipogenic differentiation, gene expression of adipocyte-specific markers was evaluated by RT-PCR. The peroxisome proliferator-activated receptor γ (PPARγ), a key transcription factor for adipogenesis, was significantly decreased in both CoCl₂ treatment groups. Moreover, the mRNA expression level of the downstream of PPARγ, adipocyte protein 2 (aP2) and CCAAT/enhancer binding protein alpha (C/EBPα), were also strongly down-regulated in treatment of CoCl₂ group compared with the control (Fig. 5C). To assess the quantitative change of mRNA expression after CoCl₂ treatment during adipogenic differentiation, qRT-PCR analysis was performed for adipogenic markers including PPARγ, aP2, and C/EBPα. The expression level of PPARγ mRNA was decreased in CoCl₂ treatment group than control through all time points. Also, mRNA expression level of aP2 and C/EBPα were substantially decreased in CoCl₂ treatment group at 5 days than control group, which markedly increased (Fig. 5D). These results indicate that treatment of CoCl₂ partially suppresses adipogenic differentiation on C3H/10T1/2 cells.

DISCUSSION

MSCs residing in the bone marrow are associated with hematopoietic stem cell functions and maintenance, and give rise to mesenchymal cell lineages including osteoblasts, chondrocytes, and adipocytes to maintain bone structures [25]. Their applicability to multiple therapeutic situations has also been investigated [9,26-29]. Additionally, the therapeutic potential of stem cells may be realized using tissue engineering approaches of developing biological tissue substitutes, and be useful at the time of implantation through in vitro cultivation [26]. Previous studies have shown that oxygen concentration can influence differentiation on many types of stem cells [30,31]. The present study investigated the differentiation potential of murine mesenchymal C3H/10T1/2 cells by hypoxia-mimetic CoCl₂ towards osteogenic, chondrogenic and adipogenic lineage commitment.

Hypoxia induces the expression of HIF-1α [30,32]. HIF-1α is the regulated part of the transcription factor heterodimer HIF-1 α/β, which complexes inside cells with another endogenous form of HIF [9]. Together these molecules enter the nucleus via an atypical hydrophobic and phosphorylation-dependent domain [8]. In the nucleus, these molecules act as transcription factors regulating gene expression. Under hypoxic conditions, HIF-1 binds to hypoxia response element in promoter regions, up-regulating certain genes involved in glucose metabolism, erythropoiesis, iron transport, control of vessel tone, and angiogenesis [33]. The major target gene for HIF-1α is vascular endothelial growth factor (VEGF); both molecules are critical regulators of angiogenic-osteogenic coupling [34,35].

In this study, to confirm the hypoxia condition by CoCl₂ treatment, expression of HIF-1α and VEGF mRNA and protein were evaluated by RT-PCR and Western blot. Treatment of CoCl₂ led to increased HIF-1α and VEGF mRNA expression in C3H/10T1/2 cells. In addition, HIF-1α protein expression was increased in CoCl₂ treated cells compared to the untreated control. Therefore, CoCl₂ appears to be an effective chemical to examine for signaling pathways involved in oxygen sensing and is useful in hypoxia response in the regulation of differentiation of MSCs.

We induced osteogenic differentiation to assess the effects of temporary CoCl₂ exposure on osteogenic capacity of MSCs. Pre-treatment of CoCl₂ for both 24 h and 48 h enhanced matrix mineralization and expression levels of osteogenic markers including OCN, OPN, ALP, Col I, and Runx2. Previous studies have demonstrated that the proportion of osteogenic cells under hypoxic conditions is greater than under normoxic conditions in vitro and in vivo [36]. These results suggest that temporary exposure to CoCl₂ may accelerate osteoblastic differentiation and matrix mineralization from MSCs.

To investigate the chondrogenic capacity of MSCs on temporary CoCl₂ exposure, we induced chondrogenic differentiation. CoCl₂ pre-treatment enhanced chondrogenesis by Alcian blue staining and increased the expression levels of chondrogenic markers including SOX9 and Col2A1. Chondrogenic differentiation of hMSCs is very distinct in hypoxia and normoxia [10]. Rat MSCs reportedly show enhanced chondrogenesis after 1 week of hypoxia [37,38]. Thus, temporary exposure to CoCl₂ may accelerate chondrogenic differentiation from MSCs.

The effect of temporary CoCl₂ exposure on adipogenic differentiation was investigated. Pre-treatment of CoCl₂ for both 24 h and 48 h suppressed adipogenesis by oil red O staining and decreased expression levels of the adipogenic markers including PPARγ, aP2, and C/EBPα. These results suggest that temporary exposure to CoCl₂ may attenuate adipogenic differentiation. Recent study revealed that the number of MSCs markedly declines and their adipogenic differentiation potential is reduced under hypoxic condition [39]. Similarly, Phorbol 12-myristate 13-acetate (PMA), a protein kinase C (PKC) activator treatment, increased osteogenic differentiation and suppressed adipogenic differentiation in human adipose-tissue-derived stromal cells.
In addition, adipogenesis in human MSCs cultured for 2 weeks under hypoxic (less than 2% O₂) condition was significantly suppressed than normoxic (approximately 18% O₂) condition [14]. On the other hands, some study reported that cell proliferation and adipogenic differentiation of mouse MSCs are triggered in hypoxia [5]. These discrepancies suggest that the cell type and hypoxic culture conditions can influence the outcomes of adipogenic differentiation.

There are two ways that can explain how CoCl₂ affects the mechanisms of MSCs differentiation. First, CoCl₂ plays a role as a hypoxia-mimicking agent which triggers p38 MAPK pathway and affects the differentiation of MSCs [41]. Second, an unknown pharmacological reaction of CoCl₂ might affect the MSCs differentiation. Though, these have not yet been clearly identified. Moreover, many studies demonstrated that variety of results can be obtained depending on the hypoxia inducing conditions.

Taken together, these results support the ability of MSCs to differentiate into osteoblasts, chondrocytes, and adipocytes in response to CoCl₂, might act through in part, HIF-1α expression. Treatment of CoCl₂, enhanced differentiation to osteoblasts and chondrocytes and suppressed differentiation to adipocytes. In this study, on the other hand, we analyzed the effects of CoCl₂ on the MSCs differentiation by controlling the concentration and the duration of CoCl₂ treatment. This study can become a meaningful reference for subsequent studies, for which proves that the MSCs differentiation can be adjusted and predicted more easily. However, potential differences between CoCl₂ treatment and hypoxia incubation in differentiation of MSCs require further studies to determine the molecular mechanism of hypoxia in MSCs lineage commitment.

ACKNOWLEDGEMENT

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP-2011-0030121) and (KRF-2010-002598).

REFERENCES

1. Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med. 2004;8:301-316.
2. Tsai CC, Chen YJ, Yew TL, Chen LL, Wang JY, Chiu CH, Hung SC. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood. 2011;117:459-469.
3. Bruder SP, Fink DJ, Caplan AI. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem. 1994;56:283-294.
4. Cicione C, Muiños-López E, Hernida-Gómez T, Fuentes-Boquete I, Díaz-Prado S, Blanco FJ. Effects of severe hypoxia on bone marrow mesenchymal stem cells differentiation potential. Stem Cells Int. 2013;2013:232896.
5. Ren H, Cao Y, Zhao Q, Li J, Zhou C, Liao L, Jia M, Zhao Q, Cai H, Han ZC, Yang R, Chen G, Zhao RC. Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochem Biophys Res Commun. 2006;347:12-21.
6. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.
7. Rosenbaum AJ, Grande DA, Dines JS. The use of mesenchymal stem cells in tissue engineering: A global assessment. Organogenesis. 2008;4:23-27.
8. Tsai CC, Yew TL, Yang DC, Huang WH, Hung SC. Benefits of hypoxia on bone marrow multipotent stromal cells. Am J Blood Res. 2012;2:148-159.
9. Das R, Jahr H, van Osch GJ, Farrell E. The role of hypoxia in bone marrow-derived mesenchymal stem cells: considerations for regenerative medicine approaches. Tissue Eng Part B Rev. 2010;16:159-168.
10. Lee HH, Chang CC, Shieh MJ, Wang JP, Chen YT, Young TH, Hung SC. Hypoxia enhances chondrogenesis and prevents terminal differentiation through PI3K/Akt/FoxO dependent anti-apoptotic effect. Sci Rep. 2013;3:2683.
11. Ercan E, Bagla AG, Aksoy A, Gacar G, Unal ZS, Asgun HF, Karaoz E. In vitro protection of adipose tissue-derived mesenchymal stem cells by erythropoietin. Acta Histochem. 2014;116:117-125.
12. Satija NK, Singh VK, Verma YK, Gupta P, Sharma S, Afrin F, Sharma M, Sharma P, Tripathi RP, Gurudutta GU. Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med. 2009;13:4385-4402.
13. Müller J, Benz K, Ahlers M, Gaissmaier C, Mollenhauer J. Hypoxic conditions during expansion culture prime human mesenchymal stromal precursor cells for chondrogenic differentiation in three-dimensional cultures. Cell Transplant. 2011;20:1589-1602.
14. Wagegg M, Gaber T, Lohanatha FL, Hahne M, Streli C, Fangradt M, Tran CL, Schöneck K, Hoff B, Ode A, Perka C, Duda GN, Buttgereit F. Hypoxia promotes osteogenesis but suppresses adipogenesis of human mesenchymal stromal cells in a hypoxia-inducible factor-1 dependent manner. PLoS One. 2012;7:e46483.
15. Holzwarth C, Vaegler M, Gieseke F, Pfister SM, Handgretinger R, Kerst G, Müller I. Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells. BMC Cell Biol. 2010;11:11.
16. Duval E, Baugé C, Andriamanalijaona R, Bénateau H, Leclercq S, Dutoit S, Poulain L, Galéra P, Boumédiène K. Molecular mechanism of hypoxia-induced chondrogenesis and its application in in vivo cartilage tissue engineering. Biomaterials. 2012;33:6042-6051.
17. Lafont JE, Talma S, Murphy CL. Hypoxia-inducible factor 2alpha is essential for hypoxic induction of the human articular chondrocyte phenotype. Arthritis Rheum. 2007;56:3297-3306.
18. Park IH, Kim KH, Choi HK, Shim JS, Whang SY, Hahn SJ, Kwon OJ, Oh IH. Constitutive stabilization of hypoxia-inducible factor alpha selectively promotes the self-renewal of mesenchymal progenitors and maintains mesenchymal stromal cells in an undifferentiated state. Exp Mol Med. 2013;45:e44.
19. Caete M. Oxygen in the cultivation of stem cells. Ann N Y Acad Sci.
20. Yang SJ, Pyen J, Lee I, Lee H, Kim Y, Kim T. Cobalt chloride-induced apoptosis and extracellular signal-regulated protein kinase 1/2 activation in rat C6 glioma cells. *J Biochem Mol Biol.* 2004;37:480-486.

21. Malda J, Klein TJ, Upton Z. The roles of hypoxia in the in vitro engineering of tissues. *Tissue Eng.* 2007;13:2153-2162.

22. Badr GA, Zhang JZ, Tang J, Kern TS, Ismail-Beigi F. Glut1 and glut3 expression, but not capillary density, is increased by cobalt chloride in rat cerebrum and retina. *Brain Res Mol Brain Res.* 1999;64:24-33.

23. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. *Blood.* 1993;82:3610-3615.

24. Yuan Y, Hilliard G, Ferguson T, Millhorn DE. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. *J Biol Chem.* 2003;278:15911-15916.

25. Cipolleschi MG, Dello Sbarba P, Olivotto M. The role of hypoxia in the maintenance of hematopoietic stem cells. *Blood.* 1993;82:2031-2037.

26. Ma T, Grayson WL, Fröhlich M, Vunjak-Novakovic G. Hypoxia and stem cell-based engineering of mesenchymal tissues. *Biotechnol Prog.* 2009;25:32-42.

27. Meijer GJ, de Bruijn JD, Koole R, van Blitterswijk CA. Cell based bone tissue engineering in jaw defects. *Biomaterials.* 2008;29:3053-3061.

28. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. *J Am Coll Cardiol.* 2005;46:1339-1350.

29. Nesselmann C, Ma N, Bieback K, Wagner W, Ho A, Konttinen YT, Zhang H, Hinescu ME, Hinescu ME, Steinhoff G. Mesenchymal stem cells and cardiac repair. *J Cell Mol Med.* 2008;12:1795-1810.

30. Park SK, Dadak AM, Haase VH, Fontana L, Giaccia AJ, Johnson RS. Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha. *J Mol Biol.* 2003;23:4959-4971.

31. Mohyeldin A, Garzón-Muvdi T, Quíñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. *Cell Stem Cell.* 2010;7:150-161.

32. Rosenberger C, Mandriota S, Jürgensen JS, Wiesener MS, Hörstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, Eckardt KU. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. *J Am Soc Nephrol.* 2002;13:1721-1732.

33. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). *Mol Pharmacol.* 2006;70:1469-1480.

34. Steinbrech DS, Mehrara BJ, Saadah PB, Chin G, Dudziak ME, Gerrets RP, Gittes GK, Longaker MT. Hypoxia regulates VEGF expression and cellular proliferation by osteoblasts in vitro. *Plast Reconstr Surg.* 1999;104:738-747.

35. Kanczler JM, Orefoo RO. Osteogenesis and angiogenesis: the potential for engineering bone. *Eur Cell Mater.* 2008;15:100-114.

36. Lennon DP, Edmison JM, Caplan AI. Cultivation of rat marrow-derived mesenchymal stem cells in reduced oxygen tension: effects on in vitro and in vivo osteochondrogenesis. *J Cell Physiol.* 2001;187:345-355.

37. Robins JC, Akeno N, Mukherjee A, Dalal RR, Aronow BJ, Koppman P, Clemens TL. Hypoxia induces chondrocyte-specific gene expression in mesenchymal cells in association with transcriptional activation of Sox9. *Bone.* 2005;37:313-322.

38. Kanichai M, Ferguson D, Prendergast PJ, Campbell VA. Hypoxia promotes chondrogenesis in rat mesenchymal stem cells: a role for AKT and hypoxia-inducible factor (HIF)-1alpha. *J Cell Physiol.* 2008;216:708-715.

39. Valorani MG, Germani A, Otto WR, Harper L, Biddle A, Khoo CP, Lin WR, Hawa MI, Tropel P, Patrizi MP, Pozzilli P, Alison MR. Hypoxia increases Sca-1/CD44 co-expression in murine mesenchymal stem cells and enhances their adipogenic differentiation potential. *Cell Tissue Res.* 2010;341:111-120.

40. Song JK, Lee CH, Hwang SM, Joo BS, Lee SY, Jung JS. Effect of phorbol 12-myristate 13-acetate on the differentiation of adipose-derived stromal cells from different subcutaneous adipose tissue depots. *Korean J Physiol Pharmacol.* 2014;18:289-296.

41. Crisostomo PR, Wang Y, Markel TA, Wang M, Lahm T, Meldrum DR. Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism. *Am J Physiol Cell Physiol.* 2008;294:C675-682.